Comparative Pharmacology
Head-to-head clinical analysis: LABETALOL HYDROCHLORIDE IN DEXTROSE versus TIMOLOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LABETALOL HYDROCHLORIDE IN DEXTROSE versus TIMOLOL.
LABETALOL HYDROCHLORIDE IN DEXTROSE vs TIMOLOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist at beta-1 adrenergic receptors (cardiac) and selective alpha-1 adrenergic receptors (vascular smooth muscle). Reduces heart rate, myocardial contractility, and peripheral vascular resistance.
Nonselective beta-adrenergic receptor antagonist (beta-blocker) that competively blocks beta-1 and beta-2 receptors, reducing heart rate, contractility, and cardiac output. In glaucoma, decreases intraocular pressure by reducing aqueous humor production.
Adult: Initial 0.5-2 mg/min IV infusion, titrate to response; typical maintenance 2-8 mg/min. Max cumulative dose 300 mg.
0.25-0.5 mg ophthalmic solution instilled twice daily; for oral: 10-20 mg twice daily.
None Documented
None Documented
Clinical Note
moderateTimolol + Digoxin
"Timolol may increase the bradycardic activities of Digoxin."
Clinical Note
moderateTimolol + Digitoxin
"Timolol may increase the bradycardic activities of Digitoxin."
Clinical Note
moderateTimolol + Deslanoside
"Timolol may increase the bradycardic activities of Deslanoside."
Clinical Note
moderateTimolol + Acetyldigitoxin
"Timolol may increase the bradycardic activities of Acetyldigitoxin."
Terminal elimination half-life: 5-8 hours (adults); 8-12 hours (elderly); 2-4 hours (children). Clinical context: half-life may be prolonged in hepatic or renal impairment.
Terminal half-life: 4-5 hours (healthy adults); prolonged to 7-10 hours in renal impairment, 11-16 hours in hepatic impairment; clinical context: once-daily dosing for hypertension/glaucoma.
Renal: 40-60% as unchanged drug and metabolites; biliary/fecal: ~50% as metabolites; <5% unchanged in feces.
Renal: ~20% unchanged; hepatic metabolism accounts for ~80%, with metabolites excreted renally; minor biliary/fecal elimination (<5%).
Category A/B
Category A/B
Alpha/Beta-Blocker
Beta-Blocker